August 09, 2016

Boehringer Ingelheim Vetmedica Inc. Introduces ULTRA™ Hybrid™ FVRCP: A New Non-Adjuvanted Feline Core Vaccine in a 0.5 mL Dose

Like all vaccines in the ULTRA line, this new product is designed to offer a more comfortable experience for the patient with 50 percent less volume.

Boehringer Ingelheim Vetmedica Inc. (BIVI), a global leader in the animal health industry, today announced the launch of ULTRA™ HYBRID™ FVRCP, a new non-adjuvanted 0.5 mL feline core vaccine. It is indicated to aid in prevention of disease caused by feline herpesvirus (viral rhinotracheitis), calicivirus infection and panleukopenia (distemper) in cats and kittens 8 weeks and older. ULTRA HYBRID FVRCP is the only combination vaccine with dual strain calicivirus shown to provide broad spectrum crossneutralization of field isolates of feline calicivirus, a medically significant disease.

“‘Hybrid’ refers to the combination of inactivated dual-strain calicivirus with a modified live feline panleukopenia and herpesvirus in one non-adjuvanted, reduced-volume vaccine,” said Arne Zislin, VMD, veterinary technical manager with BIVI. “What makes this product unique is that ULTRA HYBRID FVRCP is a non-adjuvanted feline core vaccine that contains both inactivated and MLV fractions for the most diverse protection available in a 0.5 mL vaccine.”

Like ULTRA™ Fel-O-Vax®, ULTRA HYBRID FVRCP complies with feline vaccination guidelines of both the American Association of Feline Practitioners and American Animal Hospital Association.


“Practitioners and owners know the challenges inherent with bringing many cats to a veterinary practice for essential and potentially life-saving vaccines,” said Marty Becker, DVM, founder of the Fear Free initiative. “Because of its unique formulation and resulting potential to provide a more comfortable vaccine experience, as well as less vaccine injected over the lifetime of the pet, ULTRA HYBIRD FVRCP is an ideal addition to the tools available to veterinarians to provide a Fear Free clinic experience.”

“We are pleased to offer ULTRA HYBRID FVRCP in a 0.5 mL dose, which is consistent with best practices in human vaccination to reduce volume in order to provide less pain and greater convenience1,” said Lorie R. North, director, Pet Marketing, BIVI. “Additionally, ULTRA HYBRID FVRCP is a non-adjuvanted vaccine, offering veterinarians a choice in their vaccine protocols.”

In a February 2016 survey of small-animal veterinarians with at least three years of practice experience, seven in 10 veterinarians surveyed say it’s very important to provide a “happy” vaccine experience to their patients.2

ULTRA HYBRID FVRCP is made using PureFil™ Technology, designed to decrease vaccine reactions by reducing extraneous proteins and cellular debris. Additionally, the new vaccine features an updated label with a three-part design to provide a “chain of custody” for the veterinarian, pet owner and pet. The label provides the ability to track what vaccines the pet has received in the clinic and at home. ULTRA HYBRID FVRCP is the first BIVI vaccine to have this new feature.

For more information about ULTRA HYBRID FVRCP and the complete line of ULTRA 0.5 mL vaccines, speak with a BIVI representative or visit 

1 JØrgensen J. et al, Pain Assessment of Subcutaneous Injections, The Annals of Pharmacotherapy 1996- July/August, Vol. 30

2 Data on file. 2016 Marketing Effectiveness Study conducted by Boehringer Ingelheim Animal Health